FIELD: pharmacology.
SUBSTANCE: invention provides a compound represented by the formula , or a pharmacologically acceptable salt thereof, where Ar1 and Ar2: a heteroaryl group or an aryl group; R1, R2 and R3: a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a halogenated C1-C6 alkyl group or a cyano group; R4 and R5: a hydrogen atom, a halogen atom, a C1-C6 alkyl group, a hydroxyl group or a C1-C6 alkoxy group; N: an integer between 1 and 3; and the heteroaryl group or aryl group optionally contains one or two groups, independently selected from a halogen atom, a C1-C6 alkyl group, an amino group, and when a heteroaryl group or aryl group contains two such groups, the two groups are the same or different.
EFFECT: increased efficiency of treatment.
33 cl, 5 dwg, 8 tbl, 179 ex
Title | Year | Author | Number |
---|---|---|---|
BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | 2017 |
|
RU2769827C2 |
CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
PYRIDOXAZINONE DERIVATIVES AS TNAP INHIBITORS | 2016 |
|
RU2715704C2 |
ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
COMPOUNDS AND COMPOSITIONS USED FOR TREATMENT OF NTRK-RELATED DISORDERS | 2016 |
|
RU2744974C2 |
SUBSTITUTED CHROMANS | 2015 |
|
RU2718060C2 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2014 |
|
RU2667520C9 |
ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | 2019 |
|
RU2812128C2 |
Authors
Dates
2017-11-13—Published
2013-02-08—Filed